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1078-19 Effects of the QUADDS-GP2 Drug-Eluting Stent Extend 
Beyond the Targeted Area Into Adjacent Nonstented 
Zones: Results of the SCORE Trial 
mJ. Nicholas Reifad, Jean Fajadet, Gerrnano DiSciascio, Carlo 
DiMado, Karl Hauptmann, Antonio Colombo, Roland Bach, Sigmund Silber. Eberhard 
Grube, Results of the SCORE Trial, Cardiovascularflesearch Foundation, New York, 
New York, Lenox Hi// Heari and Vascular Institute, New York, New York. 
Background: The QUADDSQP2 stent, a 316L stainless steel stent that delivers QP2 (an 
antiproliferative taxane derivative) from polymer sleeves, was shown to reduce resteno- 
sis (RS) compared to placebo in the SCORE trial (RS includes thrombosis cases). 
Whether high doses of QP2 (4000 ug), delivered through 5 high capacity polymer mem- 
branes, as used in SCORE have any impact on adjacent non-target areas is not known. 
Methods: We performed QCA on the first 260 randomized pts treated for de nova native 
lesions (134 bare metal vs 126 QP2 Stents). Follow-up QCA (MEDIS), available in 77% 
(N=202), was performed with systematic analysis of the QP2 stent area as well as 5mm 
proximal and distal adjacent non-stented segments, Results: Baseline lesion characteris- 
tics were similar in both groups, including ACC/AHA class >Bl (32%) mean vessel size 
(2.96mm), lesion length (11.6mm). and final results (final stent DS 5%). Follow-up rest- 
enosis was reduced by 72% within the QP2 stent. 67% proximal and 65% distal to the 
stent (see table). Conclusion: High dose QP2 delivered via a high capacity polymer on 
the OUEST stent demonstrated striking reductions in RS within the targeted stent zone, 
with equal effects extending at least 5mm proximally and distally beyond the confines of 
the target stent, likely representing elution of QP2 into adjacent non-stented vessel 
areas. Whether positive remodeling is the mechanism of luminal improvement at the 
edges will be detenined by IVUS. 
QUADDS-GPP QUEST 
N.99 N-103 
p value 
Fketenosis Stent(%) 
FU Proximal Edge DS, % 
Restenosls Prox Edge % 
FU distal Edge DS, % 
Reatenosls Distal Edae f%t 
10.1% 36.9% 0.0001 
24*21 35+24 0.0007 
9.3% 26.4% 0.0006 
16*16 25+22 0.001 
5.2% 14.7% 0.0267 
1078-20 Comparison of a Novel Polymer (PLLg-PEG) With Gold- 
Coated and Stainless Steel Stents for Prevention of 
Neolntlmal Hyperplasia 
7, Katja S. Gdgioni. Jeffrey A. Hubbell, Thomas Schaffner, Beat 
Walooth. Daniel MettIer. Franz R. Eberli. Bernhard Meier. Otto M Hess, Swiss 
Cardiovascular Center Bern, Bern, Switzerland, Swiss Federal institute of Technology. 
Zurich. 
Background: Stent coating aims to reduce neointimal hyperplasia. The purpose of this 
study was to investigate the effect of a novel polymer (poly_L-lysine with polyethylene- 
glycol=PLL-g-PEG) on neointimal hyperplasia and to compare it with gold-coated and 
stainless steel stents in the porcine restenosis model. 
Methods: Three different (NIR) stents were implanted each in a total of 13 pigs: (I) an 
uncoated, stainless steel stent (control=bare NIR stent), (2) a polymer-coated stent (PLL- 
g-PEG dip-coated on a bare NIR stent), and (3) a gold-coated stent (NIR Royal). Stents 
were randomly implanted into either the left anterior descending, left circumflex or right 
coronary artery. Stent length and diameter were t6 mm and 3.0 mm. respectively. Infla- 
tion pressure was adjusted to achieve a balloon-to-artery ratio of 1 .l :l Six weeks after 
implantation, animals were restudied by quantitative coronary angiography, and then 
stented arteries were examined by digttal histomorphometry. 
Results: At follow-up angiography, all stents were expanded and patent. Angiographic 
restenosis was 14r6% for the control, 9*7% for the polymer-coated and 2129% for the 
gold-coated stents (p<O.O4). Histologic examination showed no evidence of thrombus 
formation or inflammatory cells surrounding the stent struts. Quantitative histomorphom- 
etry revealed a significant decrease in luminal area for gold-coated stents (4.6Oi2.14 
mm2) compared with the control (5.56k2.2 mm2) and polymer-coated stents (5.6152.0 
mm2. ANOVA p<O.Ol). Neointimal hyperplasia amounted to 2.54kO.63 mm2 in control, 
2.17iO.61 mm2 in polymer-coated and 2.95i1.16 mm2 in gold-coated stents (ANOVA 
p<O.OOl). Histologic restenosis rate was 34*16% in control, 29214% in polymer-coated, 
and 41+19% in gold-coated stents (ANOVA p<O.O03). 
Conclusions: Surface modifications of stainless steel stents by passive coatings modify 
the amount of neointimal proliferation in the porcine restenosis model. Polymer-coating 
with PLL-g-PEG significantly reduces neointimal proliferation, whereas gold enhances 
neointimal formation compared with stainless steel. Thus, stent coating with PLL-g-PEG 
may be beneficial for prevention of instant restenosis. 
1078-21 Dramatic Inhibition of Neolntimal Prollferatlon by the 
Paclltaxel-Eluting Stents Showing Radiation-Llke 
Results Without Radiation: Insights From the QCA Core 
Laboratory 
m, Albert E. Raizner, SeungJung Park, Won-Heum Shim, David S. Ho, 
William D. Voorhees, Neal E. Fearnot. The Methodist DeBakey Heart Centsrand Baylor 
College of Medicine, Houston, Texas. 
Background: Even in the absence of clinically relevant restenosis, neointimal prolifera- 
tion within the conventional metallic stent results in approximately 30% loss of lumen 
diameter achieved by the stent implantation. Preliminary data suggest that local drug 
delivery directly from the stant surface is affective in reducing the restenosis rate. We 
sought to determine if paclitaxel eluted from the stent surface could change the pattern of 
restenosis by significantly minimizing the in-stent proliferation and thus better preserving 
the post-procedural gain. 
Methods: ASPECT was a dose-finding trial comparing restenosis in stents eluting pacli- 
taxel to control (conventional stents) at 4 to 6 month follow-up. While both doses signifl- 
cantly reduced restenosls as compared to control, the higher dose was most effective 
without apparent differences in safety. Of 177 patients enrolled, 60 patients received 
high-dose pactllel-coated stents. By the analysis of the quantitative coronary angicgra- 
phy (DCA) data, we calculated the incidence of percent diameter stenosis of less than 
5% at the follow-up, which would indicate extraordinary inhibition of nsointimal growth. 
Results: Dt patients in the high dose paclitaxel-coated stent group, 96% had a percent 
diameter stenosis of less than 50% (Le. no binary restenosis) at the follow-up. More nota- 
bly, 46% patients presented at the follow-up with percent diameter stenosis of 5% or less, 
compared to only 9% in the control group (p<.OOOl). There were no late thrombotic 
events. 
Conclusion: The paclitaxel-eluting stent is capable of extraordinary inhibition of neointi- 
mal proliferation. This inhibition most likely does not occur at the cost of impaired vessel 
healing and reendothellalization since it was not associated with late thrombotic events. 
This pattern of minimal neointimal stent “paving” is fundamentally different from the 
thicker rind of neointimal growth almost invariably induced by conventional metallic 
stents. 
1078-22 A Quantitative Assessment of Regional Changes In 
Lumen Diameter After Photodynamic Therapy With 
Motexafin Lutetium in Patients Undergoing Stent 
Implantation 
JeffrevJ.Pooma. Nicholas Cox, Dennis Wahr, Howard Herrmann, Daniel I. Simon, 
Campbell D. Rogers, Paul Kramer, Wendy Shear, Kendrtck Shunk, Alan Yeung, Ross 
Prpic, Daniel Adelman, Dean Kereiakes. Brigham and Women’s Hospital, Boston, 
Massachusetts. 
Background Motexafin lutetium (MLu. Antrin” Injection) is a synthetic expanded por- 
phyrin-photosensitizing agent that localizes in atheroma. Upon activation of MLu with 
intra-arterial 732 nm light, singlet oxygen is produced and apoptosis of inflammatory cells 
occurs. Preliminary data suggests a potential benefit of MLu for restenosis, but its effects 
at the light therapy edges are unknown. Methods: We quantitatively analyzed clneangio- 
grams obtained from 56 patients who underwent stent placement and were enrolled in a 
phase I drug and light escalation study (Group I: MLu dose range: 0.05-4.0 @kg; light 
range: 100 J/cm-fiber: Group II: MLu dose 2.0-3.0 mmg; light range: 200600 J/cm- 
fiber). Image frames were compared before (BL) and just after endovascular illumination, 
and 6 months (FU) later. Analysis zones included the stent, injured segment, lighted seg- 
ment, vessel, and a 5 mm segment proximal and distal to the light source. Results: Ret- 
erehce diameters measured 5 mm proximal and distal to the light source did not change 
during FU (EL: 2.63 ho.45 mm; FU 2.63 ~0.44 mm). Mean % stenosis at FU were 
41 .l% within the stent, 41.5% within the injured segment, 42.7% within the lighted seg 
ment, and 44.2% in the vessel. In-stent binary restenosis was 39.5% in Group I and 
26.3% in Group II. Lumen changes at the proximal (0.17 ~0.56 mm) or distal (0.04 rt 
0.42mm) ends were not consistent with an “edge effect.” Conclusions: Treatment with 
MLu in patients undergoing stent implantatlon resulted in no deleterious lumen changes 
at the edge of the treatment zone (Le.. no “edge effect”). Restenosis was primarily 
located within the axial stent length and indicated an early dose and light response in its 
etfect on restenosis. Further analysis of the potential biologic activity of MLu on the 
lighted but uninjured atherosclerotic regions is ongoing. 
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1079-8 Unfractionated Heparin Reduces the Antlplatelet Effects 
of Abciximab but Not Eptifibatide During Coronary 
Interventions 
, Laura G. Metton, Cheryl Thompson, Melrose Fisher, Don A. 
Gabriel, Gregory J. Dehmer, University of Norfh Carolina, Chapel Hi//, North Carolina, 
Wake Forest University School of Medicine. Winston-Salem, North Carolina. 
Background: Abciximab (AB) and Eptifibatide (EP) are both effective during PCI, how- 
ever only EP has proven beneficial as an adjuvant medical treatment for ACS. We 
hypothesized that the concomitant use of unfractionated heparin (UFH) may differentially 
effect the degree of platelet inhibition produced by AB and EP. Methods: In 26 pts under- 
going PCI we obtained samples at baseline, 10 min after standard weight-based AB 
(11~14) or double-bolus EP (n=14) and 5 min after UFH (70 U/kg bolus). Percent inhibition 
of platelet aggregation was assessed after both weak (ADP) and strong (TRAP) platelet 
agonism and calculated based on the baseline values. All pts had received aspirin and 
300 mg of clopidogrel. Results: Mean % inhibition was higher in EP pts compared with 
AB pts both before (96 vs 65% [ADP]; 69 vs 63% (TRAP], p<O.OOl for both) and after 
UFH (96 vs 79% [ADP]; 61 YS 52% [TRAP], pcO.001). Addiiion of UFH significantly 
reduced platelet inhibition in AB pts (65 YS 79% [ADP]; 63 YS 52% (TRAP], ~~0.05 for 
both) but not in EP pts (96 vs 96% [ADP]; 69 vs 61% [TRAP]; p=ns for both). Following 
addition of UFH none of AB pts compared with 57% of EP pts achieved the “optimal’ 
>60% inhibition of platelet aggregation (Figure). Concluslons: With standard dosing, EP 
